Sign-up for our New Digital Chart System Here

BLOG POSTS

Allergan textured breast implants pulled from the U.S. market

Today’s news was no surprise.  Textured implants from the manufacturer Allergan were pulled from the U.S. market, following the UK, France and Canada.

Textured implants from Allergan were pulled from the U.S. market today.

I have never been a fan of textured implants and I don’t use them in my practice.  The gel is too stiff, being the most highly cohesive gel.  The textured surface has a Velcro-like effect, causing scar tissue to stick directly to it and limiting movement of the implant in the pocket.  They also can have more rippling that tends to be visible through the skin due to the scar tissue sticking to the implant surface.

And now that there is ongoing review into cases of a very rare subtype of lymphoma called breast implant-associated anaplastic large cell lymphoma (bia-ALCL), it just makes sense for the manufacturer to stop selling them.

But I do use Allergan implants, all the time!  The Allergan breast implants I use are smooth round silicone gel breast implants .  Learn more about the breast implants I use in my practice here.

Here is the press release, hot off the wire:

Allergan announces worldwide recall of Biocell textured implants

Allergan announced this morning that it is recalling its Biocell textured breast implants and tissue expanders.

The move follows increased scrutiny on textured breast implants and their connection to BIA-ALCL, an uncommon lymphoma that can develop around breast implants. The U.S. Food and Drug Administration (FDA) requested that Allergan recall specific models of its textured breast implants from the U.S. market due to the risk of BIA-ALCL, and Allergan agreed to voluntarily issue the recall as a precautionary measure.

Biocell saline-filled and silicone-filled textured implants and tissue expanders will no longer be distributed or sold in any market where they are currently available. The company urged healthcare providers to cease implanting its Biocell products and return any unused devices to Allergan.

The recall does not affect the company’s Natrelle smooth or Microcell breast implants or expanders.

“As plastic surgeons, patient safety is always our top priority,” says ASPS President Alan Matarasso, MD. “The Society will continue to study BIA-ALCL through the PROFILE registry and provide updated information and resources to physicians and the public. This development underscores the need for all plastic surgeons to enter all breast implant cases into the National Breast Implant Registry (NBIR) and all ALCL cases into the PROFILE registry.”

The FDA notes that women who have these implants but no symptoms, do not need to have them removed. Common symptoms include breast enlargement, pain, asymmetry, lump in the breast or armpit, overlying skin rash, hardening of the breast or a large fluid collection typically developing after receiving an implant and, on average, after 8 to 10 years.

ASPS provides a wealth of information on breast-implant safety and BIA-ALCL, including facts, statistics, informed-consent language, insurance coverage information and a list of frequently asked questions for both doctors and patients at plasticsurgery.org/alcl.

The PROFILE registry contains a total of approximately 288 cases of ALCL in the US and 735 worldwide since the initial case report in 1996. The PROFILE registry contains cases which are voluntarily reported and may not accurately reflect the actual number of cases.

“Through the National Breast Implant Registry (NBIR), a collaboration between The Plastic Surgery Foundation, ASPS and the FDA, plastic surgeons are gathering data to improve safety of the device,” says The PSF President Andrea Pusic, MD, MHS. “It is very important for all plastic surgeons to enter all implant-based cosmetic and reconstructive breast surgery cases into NBIRand any BIA-ALCL cases into PROFILE.”

ASPS members are also encouraged to participate in the National Breast Implant Registry and can register at thepsf.org/nbir. Additionally, the FDA recommends that any suspected or confirmed cases of BIA-ALCL be reported to the PROFILE registry at thepsf.org/profile; to the FDA’s Manufacturers and User Facility Device Experience (MAUDE) database; and to the device manufacturer.

Read the Allergan statement »

Read the FDA statement »

What does this mean for women who already have textured implants in place?  Don’t panic.  Educate yourself about the signs and symptoms of ALCL in the resources listed in my ALCL blog post.  See a Board Certified Plastic Surgeon for evaluation, and stay informed about further information as it is available.

To learn more, visit my website or call 415-923-3067 for additional information.

Karen M. Horton, MD, MSc, FACS, FRCSC

San Francisco Board Certified Plastic Surgeon

Subscribe to our Blog

Enter your Name and Email to receive all our latest blog posts.
Dr Karen Horton